Middle East And Africa Acne Medication Market

Middle East and Africa Acne Medication Market was worth USD xx billion in 2018 and estimated to be growing at a CAGR of xx%, to reach USD xx billion by 2023. Acne is a skin disease which is characterized by pimples, oily skin and blackheads. It can be caused due to dead skin cells, clogged hair follicles and oil from the skin. It generally affects the region with a considerably higher number of sweat glands like upper part of chest, back and face.

Unhealthy urban lifestyle and growing number of cases of acne are the major factors driving the market growth. As people are becoming conscious about their looks, the market is expected to propel during the forecast period. However, side effects associated with the use of acne medication and alternative treatments available in the market are hampering the market growth.

The market for Acne Medication is broadly categorized into type, route of administration and drug class. By type the market is divided into OTC and prescription drugs. By route of administration the market is segmented into Oral and topical. By drug class the market is classified into Antibiotics, anti-inflammatory drugs, anti microbial, combination drugs, hormonal agents, oral retinoids and topical retinoids. Anti-inflammatory segment holds a major share of the market revenue. On the basis of geography, the market is analysed under various regions namely Middle East and Africa .

Some of the major companies dominating the market, by their products and services include Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V., and Daiichi Sankyo Company, Ltd.,